共 50 条
- [1] Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH StudyHEPATOLOGY COMMUNICATIONS, 2021, 5 (06) : 938 - 946Barritt, A. SidneyWatkins, StephanieGitlin, NormanKlein, SamuelLok, Anna S.Loomba, RohitSchoen, CherylReddy, K. RajenderTrinh, Huy NgocMospan, Andrea R.Vos, Miriam B.Weiss, L. MichaelCusi, KennethNeuschwander-Tetri, Brent A.Sanyal, Arun J.
- [2] Real world evidence showing high rates of cardiovascular events in NAFLD patients regardless of liver diseaseJOURNAL OF HEPATOLOGY, 2018, 68 : S828 - S828Sanyal, A.Cusi, K.Firpi, R. J.Gitlin, N.Levy, C.Malahias, L.Reddy, R.Schoen, C.Weiss, L. M.Lok, A.
- [3] Concordance of MASLD and NAFLD nomenclature in youth participating in the TARGET-NASH real-world cohortHEPATOLOGY COMMUNICATIONS, 2024, 8 (11)Sanchez-Torres, CristianTovar, Ana RamirezChatman, KelseyMorris, Heather L.Yu, FengMospan, Andrea R.Diehl, Anna MaeLeung, Daniel H.Viswanathan, PreetiSquires, James E.Palle, SirishVos, Miriam B.
- [4] THE ROLE OF DISEASE SEVERITY AND GENDER IN POLYPHARMACY AMONG PATIENTS WITH NAFLD ENROLLED IN TARGET-NASHHEPATOLOGY, 2022, 76 : S826 - S827Al-Sayyed, LeenMorris, HeatherMospan, AndreaHernandez, Breda MunozAbraham, SheenuFried, MichaelBarritt, Sidney SidneyTetri, Brent A.
- [5] PATTERNS OF MEDICATION USE AMONG ADULT PATIENTS WITH ELEVATED SERUM ALT LEVELS IN PATIENTS WITH NAFLD: TARGET-NASHHEPATOLOGY, 2019, 70 : 734A - 734ABarritt, Alfred SidneyWatkins, StephanieNeuschwander-Tetri, Brent A.Schoen, CherylDesai, RoshaniVos, Miriam B.Malahias, LauraMalespin, Miguel H.Newsome, Philip N.Reddy, K. RajenderTaunk, Jawahar L.Firpi, Roberto J.Sanyal, Arun J.
- [6] Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH studyCONTEMPORARY CLINICAL TRIALS, 2017, 61 : 33 - 38Barritt, A. S.Gitlin, NormanKlein, SamuelLok, Anna S.Loomba, RohitMalahias, LauraPowell, MargaretVos, Miriam B.Weiss, L. MichaelCusi, KennethNeuschwander-Tetri, Brent A.Sanyal, Arun
- [7] WEIGHT LOSS AND CHANGE IN ALANINE AMINOTRANSFERASE (ALT) AMONG PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) RECEIVING STANDARD CARE IN REAL WORLD CLINICAL PRACTICE: TARGET-NASHGASTROENTEROLOGY, 2020, 158 (06) : S1418 - S1418Moon, Andrew M.Watkins, StephanieMalespin, MiguelSchoen, CherylWeiss, L. MichaelLoomba, RohitThuluvath, Paul J.Reddy, K. RajenderBarritt, Alfred S.Sanyal, Arun J.Neuschwander-Tetri, Brent A.
- [8] Weight loss and change in alanine aminotransferase (ALT) among patients with non-alcoholic fatty liver disease (NAFLD) receiving standard care in real world clinical practice: TARGET-NASHJOURNAL OF HEPATOLOGY, 2020, 73 : S441 - S441Moon, AndrewWatkins, StephanieMalespin, MiguelSchoen, CherylWeiss, L. MichaelLoomba, RohitThuluvath, Paul J.Reddy, RajenderBarritt, A. SidneySanyal, ArunTetri, Brent
- [9] Real-world use of Glucagon-like peptide 1 receptor agonists in patients with MASLD: a cross-sectional analysis from TARGET-NASHJOURNAL OF HEPATOLOGY, 2024, 80 : S610 - S610Barritt, A. SidneyMospan, AndreaMorris, HeatherPerez, AnthonyLoomba, RohitFried, MichaelSanyal, Arun J.Newsome, Philip N.
- [10] Non-alcoholic steatohepatitis disease progression in participants from the United States TARGET-NASH real world longitudinal observational studyJOURNAL OF HEPATOLOGY, 2023, 78 : S72 - S72Sartini, ClaudioRudolph, BryanFraessdorf, MandyMorris, HeatherGazis, DerekMospan, AndreaFried, MichaelRoden, MichaelTetri, BrentCusi, KennethNewsome, Philip N.